Skip to content
2000
Volume 17, Issue 4
  • ISSN: 1872-2105
  • E-ISSN: 2212-4020

Abstract

COVID-19, caused by the SARS-CoV-2 virus, has been expanding. SARS-CoV caused an outbreak in early 2000, while MERS-CoV had a similar expansion of illness in early 2010. Nanotechnology has been employed for nasal delivery of drugs to conquer a variety of challenges that emerge during mucosal administration. The role of nanotechnology is highly relevant to counter this “virus” nano enemy. This technique directs the safe and effective distribution of accessible therapeutic choices using tailored nanocarriers, as well as the interruption of virion assembly, by preventing the early contact of viral spike glycoprotein with host cell surface receptors. This study summarises what we know about earlier SARS-CoV and MERS-CoV illnesses, with the goal of better understanding the recently discovered SARS-CoV-2 virus. It also explains the progress made so far in creating COVID-19 vaccines/ treatments using existing methods. Furthermore, we studied nanotechnology- based vaccinations and therapeutic medications that are now undergoing clinical trials and other alternatives.

Loading

Article metrics loading...

/content/journals/nanotec/10.2174/1872210516666220819104853
2023-12-01
2025-09-12
Loading full text...

Full text loading...

/content/journals/nanotec/10.2174/1872210516666220819104853
Loading

  • Article Type:
    Review Article
Keyword(s): COVID-19; immune system; MERS-CoV; nanotechnology; SARS-CoV-2; treatment
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test